SCHEMBL1870547

SCHEMBL1870547

N=C(CCC(=O)OC(=O)CCCCCCCC(=O)O)OC(=O)CCCCCCCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.48
LMNA P02545 3/20 0.48
NFKB1 P19838 1/20 0.48
PMP22 Q01453 1/20 0.48
GPR84 Q9NQS5 8/20 0.41
FFAR1 O14842 2/20 0.41
FFAR4 Q5NUL3 2/20 0.41
ALDH1A1 P00352 4/20 0.41
PPARG P37231 6/20 0.40
PPARD Q03181 6/20 0.40
PPARA Q07869 6/20 0.40
HDAC11 Q96DB2 5/20 0.40
TLR2 O60603 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 2/20 0.40
FABP4 P15090 2/20 0.40
ALOX15 P16050 2/20 0.40
PTPN1 P18031 2/20 0.40
KMT2A Q03164 2/20 0.40
SLC22A6 Q4U2R8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905699 1.00 TSHR (0.48) TSHRLMNANFKB1PMP22GPR84
SCHEMBL905402 1.00 TSHR (0.48) TSHRLMNANFKB1PMP22GPR84
SCHEMBL905720 1.00 TSHR (0.48) TSHRLMNANFKB1PMP22GPR84
SCHEMBL379359 1.00 TSHR (0.48) TSHRLMNANFKB1PMP22GPR84
SCHEMBL1230057 1.00 TSHR (0.48) TSHRLMNANFKB1PMP22GPR84
SCHEMBL290459 0.98 LMNA (0.46) TSHRLMNANFKB1PMP22GPR84
SCHEMBL34381 0.94 TSHR (0.48) TSHRLMNANFKB1PMP22GPR84
Ethylene Glycol SCHEMBL6523934 0.89 TSHR (0.44) TSHRLMNANFKB1PMP22GPR84
SCHEMBL43574 0.87 EGLN1 (0.43) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL8405060 0.87 TSHR (0.63) TSHRLMNANFKB1PMP22GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724117-A2 METHOD OF TREATING AN ARTICULAR CONDITION OR A CONDITION OF A BONY CANAL Ocular Therapeutix, Inc. (US) 2026-04-15 EP claimed
EP-4683964-A2 POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2026-01-28 EP claimed
EP-4665307-A1 BIODEGRADABLE MICROPARTICLES FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2025-12-24 EP claimed
EP-4630058-A2 CHEMICAL TISSUE ABLATION WITH HYDROGEL MATRIX AND CORRESPONDING MEDICAL APPLICATIONS Pramand LLC (US) 2025-10-15 EP claimed
EP-4568658-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2025-06-18 EP claimed
US-20250144012-A1 INTRACAMERAL DRUG DELIVERY DEPOTS INCEPT, LLC 2025-05-08 US claimed
CN-119947711-A Organogels for sustained drug delivery, methods of preparation and uses thereof 视尔普斯眼科公司 2025-05-06 CN claimed
US-12251466-B2 Single solution hydrogels with covalent bonding formed in situ, composition design and medical procedures using the hydrogels Pramand LLC (US) 2025-03-18 US claimed
EP-4518920-A1 WATER ACTIVATED HYDROGEL-BASED MEDICAL PATCHES, FLEXIBLE SUBSTRATES AND METHODS OF MAKING AND USING SUCH PATCHES Pramand LLC (US) 2025-03-12 EP claimed
CN-119587480-A Compositions and methods for treating ocular disorders 视尔普斯眼科公司 2025-03-11 CN claimed
WO-2024035690-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF OCULAR THERAPEUTIX, INC. (US) 2024-02-15 WO claimed
EP-4279064-A2 DRUG DELIVERY FROM HYDROGELS Incept, LLC (US) 2023-11-22 EP claimed
WO-2023215453-A1 WATER ACTIVATED HYDROGEL-BASED MEDICAL PATCHES, FLEXIBLE SUBSTRATES AND METHODS OF MAKING AND USING SUCH PATCHES Pramand LLC (US) 2023-11-09 WO claimed
US-20230338286-A1 SINGLE SOLUTION HYDROGELS WITH COVALENT BONDING FORMED IN SITU, COMPOSITION DESIGN AND MEDICAL PROCEDURES USING THE HYDROGELS Pramand LLC 2023-10-26 US claimed
WO-2023205051-A1 SINGLE SOLUTION HYDROGELS WITH COVALENT BONDING FORMED IN SITU, COMPOSITION DESIGN AND MEDICAL PROCEDURES USING THE HYDROGELS Pramand LLC (US) 2023-10-26 WO claimed
EP-3294212-B1 DRUG DELIVERY FROM HYDROGELS INCEPT LLC (US) 2023-10-25 EP claimed
WO-2023150580-A2 A CONTROLLED RELEASE IMPLANT FOR BIOLOGICS AND CORRESPONDING METHODS OF TREATMENT OCULAR THERAPEUTIX, INC. (US) 2023-08-10 WO claimed
EP-4197527-A1 INTRACAMERAL DRUG DELIVERY DEPOTS Incept, LLC (US) 2023-06-21 EP claimed
US-20220401356-A1 INTRACAMERAL DRUG DELIVERY DEPOTS INCEPT, LLC 2022-12-22 US claimed
CN-115066232-A Compositions and methods for treating ocular diseases 视觉治疗股份有限公司 2022-09-16 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144012-A1 INTRACAMERAL DRUG DELIVERY DEPOTS MMP1, UACA, IDE TSHR 994/4885LMNA 2426/4885NFKB1 816/4885
US-20220401356-A1 INTRACAMERAL DRUG DELIVERY DEPOTS MMP1, UACA, IDE TSHR 994/4885LMNA 2426/4885NFKB1 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.